(Q44444279)

reason for preferred rank

3 December 2017

title

Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04330.X

3 January 2024

Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752112

3 January 2024

1 reference

Julian Topaly

1

1 reference

3 December 2017

Moritz Schad

2

1 reference

3 December 2017

Stephanie Laufs

3

1 reference

3 December 2017

Stefan Fruehauf

6

1 reference

3 December 2017

Junia V. Melo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752112

3 January 2024

W. Jens Zeller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752112

3 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

3 December 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2141.2003.04330.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752112

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.2003.04330.x

3 January 2024

1 reference

DOI

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04330.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.2003.04330.x

3 January 2024

1 reference

DOI

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04330.X

British Journal of Haematology

3 January 2024

published in

1 reference

3 December 2017

volume

121

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

672-673

1 reference

STI571 (Gleevec) as a paradigm for cancer therapy

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04330.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference